342 related articles for article (PubMed ID: 27927793)
41. DNA methylation based biomarkers in colorectal cancer: A systematic review.
Lam K; Pan K; Linnekamp JF; Medema JP; Kandimalla R
Biochim Biophys Acta; 2016 Aug; 1866(1):106-20. PubMed ID: 27385266
[TBL] [Abstract][Full Text] [Related]
42. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic Regulation and Drug Discovery for Cancer Therapy.
Yu B; Ouyang L
Curr Top Med Chem; 2019; 19(12):971. PubMed ID: 31486748
[No Abstract] [Full Text] [Related]
44. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
45. miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer.
Zubor P; Kubatka P; Dankova Z; Gondova A; Kajo K; Hatok J; Samec M; Jagelkova M; Krivus S; Holubekova V; Bujnak J; Laucekova Z; Zelinova K; Stastny I; Nachajova M; Danko J; Golubnitschaja O
Future Oncol; 2018 Aug; 14(18):1847-1867. PubMed ID: 30019928
[TBL] [Abstract][Full Text] [Related]
46. Methods for cancer epigenome analysis.
Nagarajan RP; Fouse SD; Bell RJ; Costello JF
Adv Exp Med Biol; 2013; 754():313-38. PubMed ID: 22956508
[TBL] [Abstract][Full Text] [Related]
47. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target.
Juergens RA; Rudin CM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714528
[TBL] [Abstract][Full Text] [Related]
48. The role of piRNA and its potential clinical implications in cancer.
Assumpção CB; Calcagno DQ; Araújo TM; Santos SE; Santos ÂK; Riggins GJ; Burbano RR; Assumpção PP
Epigenomics; 2015; 7(6):975-84. PubMed ID: 25929784
[TBL] [Abstract][Full Text] [Related]
49. Epigenetics: Unravelling the cancer code.
Brower V
Nature; 2011 Mar; 471(7339):S12-3. PubMed ID: 21430711
[No Abstract] [Full Text] [Related]
50. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
51. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
52. The Future of Precision Oncology for the Treatment of Solid Tumors.
Klute KA
Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
[No Abstract] [Full Text] [Related]
53. Cancer Genetics and Implications for Clinical Management.
Jamieson NB; Chang DK; Biankin AV
Surg Clin North Am; 2015 Oct; 95(5):919-34. PubMed ID: 26315514
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications.
Porcellini E; Laprovitera N; Riefolo M; Ravaioli M; Garajova I; Ferracin M
Cancer Lett; 2018 Apr; 419():84-95. PubMed ID: 29360561
[TBL] [Abstract][Full Text] [Related]
55. Epigenome-based personalized medicine in human cancer.
Yan W; Herman JG; Guo M
Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
[TBL] [Abstract][Full Text] [Related]
56. Epigenetics in cancer therapy and nanomedicine.
Roberti A; Valdes AF; Torrecillas R; Fraga MF; Fernandez AF
Clin Epigenetics; 2019 May; 11(1):81. PubMed ID: 31097014
[TBL] [Abstract][Full Text] [Related]
57. Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy.
Hussain S; Tulsyan S; Dar SA; Sisodiya S; Abiha U; Kumar R; Mishra BN; Haque S
Semin Cancer Biol; 2022 Aug; 83():441-451. PubMed ID: 34182144
[TBL] [Abstract][Full Text] [Related]
58. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
Bonzheim I; Fend F
Pathologe; 2014 Feb; 35(1):93-105. PubMed ID: 24496994
[TBL] [Abstract][Full Text] [Related]
59. GSDME: A Potential Ally in Cancer Detection and Treatment.
Ibrahim J; De Schutter E; Op de Beeck K
Trends Cancer; 2021 May; 7(5):392-394. PubMed ID: 33422423
[TBL] [Abstract][Full Text] [Related]
60. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
